Emerging concepts on inhibitors of indoleamine 2,3-dioxygenase in rheumatic diseases

Current Medicinal Chemistry

Volumn 19, Issue 31, 2012, Pages 5381-5393

  Filippini, P ^a   Del Papa, N ^b   Sambataro, D ^c   Del Bufalo, A ^d   Locatelli, F ^e,f   Rutella, S ^d,e  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^c CANNIZZARO HOSPITAL   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

Autoimmunity; Cancer; Dendritic cell; Hematopoietic growth factors; Immune tolerance; Indoleamine 2,3 dioxygenase; Interferon ; Regulatory T cell; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

1 METHYL DEXTRO TRYPTOPHAN; ALPHA INTERFERON; BETA INTERFERON; BETA1 INTEGRIN; C REACTIVE PROTEIN; CD18 ANTIGEN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; IMATINIB; INCB 024360; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; IPILIMUMAB; KYNURENIC ACID; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; ARTHRITIS; ARTICLE; B LYMPHOCYTE; BIOAVAILABILITY; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE ESCALATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; FIBROBLAST; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HELPER CELL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MACROPHAGE; MELANOMA CELL; METASTATIC MELANOMA; MORTALITY; MUTATION; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; STROMA CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TH1 CELL; TH17 CELL; TUMOR GROWTH;

ANIMALS; ARTHRITIS, RHEUMATOID; ENZYME INHIBITORS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC; SJOGREN'S SYNDROME; TRYPTOPHAN;

EID: 84870449163     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803833353     Document Type: Article

References (147)

1. Mellor, A.L.; Munn, D.H., IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol., 2004, 4, (10), 762-774.
2. Lancellotti, S.; Novarese, L.; De Cristofaro, R., Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors. Curr Med Chem, 2011, 18, (15), 2205-2214.
3. Munn, D.H.; Zhou, M.; Attwood, J.T.; Bondarev, I.; Conway, S.J.; Marshall, B.; Brown, C.; Mellor, A.L., Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 1998, 281, (5380), 1191-1193.
4. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B.J., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med., 2003, 9, (10), 1269-1274.
5. Bonanno, G.; Corallo, M.; Mariotti, A.; Di Maggio, A.; Procoli, A.; De Rosa, L.; Pierelli, L.; Majolino, I.; Leone, G.; De Cristofaro, R.; Rutella, S., Indoleamine 2,3-dioxygenase (IDO) is expressed by multiple myeloma plasma cells and promotes the differentiation of regulatory T cells: Investigations into the role of hepatocyte growth factor. Blood, 2008, 112, (2), 1680A.
6. Munn, D.H., Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr. Opin. Immunol., 2006, 18, (2), 220-225.
7. Fallarino, F.; Grohmann, U.; Vacca, C.; Bianchi, R.; Orabona, C.; Spreca, A.; Fioretti, M.C.; Puccetti, P., T cell apoptosis by tryptophan catabolism. Cell Death Differ, 2002, 9, (10), 1069-1077.
8. Takikawa, O.; Yoshida, R.; Kido, R.; Hayaishi, O., Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J. Biol. Chem., 1986, 261, (8), 3648-3653.
9. Munn, D.H.; Sharma, M.D.; Mellor, A.L., Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol., 2004, 172, (7), 4100-4110.
10. Shevach, E.M., CD4+CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol., 2002, 2, (6), 389-400.
11. Niederkorn, J.Y., Emerging concepts in CD8+ T regulatory cells. Curr. Opin. Immunol., 2008, 20, (3), 327-331.
12. Sica, A.; Bronte, V., Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest., 2007, 117, (5), 1155-1166.
13. Terabe, M.; Berzofsky, J.A., NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol, 2007, 28, (11), 491-496.
14. Lu, L.F.; Lind, E.F.; Gondek, D.C.; Bennett, K.A.; Gleeson, M.W.; Pino-Lagos, K.; Scott, Z.A.; Coyle, A.J.; Reed, J.L.; Van Snick, J.; Strom, T.B.; Zheng, X.X.; Noelle, R.J., Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature, 2006, 442, (7106), 997-1002.
15. Rutella, S.; Danese, S.; Leone, G., Tolerogenic dendritic cells: cytokine modulation comes of age. Blood, 2006, 108, (5), 1435-1440.
16. Gabrilovich, D.I.; Bronte, V.; Chen, S.H.; Colombo, M.P.; Ochoa, A.; Ostrand-Rosenberg, S.; Schreiber, H., The terminology issue for myeloidderived suppressor cells. Cancer Res, 2007, 67, (1), 425.
17. Munn, D.H.; Sharma, M.D.; Lee, J.R.; Jhaver, K.G.; Johnson, T.S.; Keskin, D.B.; Marshall, B.; Chandler, P.; Antonia, S.J.; Burgess, R.; Slingluff, C.L., Jr.; Mellor, A.L., Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science, 2002, 297, (5588), 1867-1870.
18. Chen, W.; Liang, X.; Peterson, A.J.; Munn, D.H.; Blazar, B.R., The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol., 2008, 181, (8), 5396-5404.
19. Munn, D.H.; Sharma, M.D.; Hou, D.; Baban, B.; Lee, J.R.; Antonia, S.J.; Messina, J.L.; Chandler, P.; Koni, P.A.; Mellor, A.L., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumordraining lymph nodes. J. Clin. Invest., 2004, 114, (2), 280-290.
20. Johnson, B.A., 3rd; Kahler, D.J.; Baban, B.; Chandler, P.R.; Kang, B.; Shimoda, M.; Koni, P.A.; Pihkala, J.; Vilagos, B.; Busslinger, M.; Munn, D.H.; Mellor, A.L., B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, (23), 10644-10648.
21. Ratajczak, P.; Janin, A.; Peffault de Larour, R.; Koch, L.; Roche, B.; Munn, D.; Blazar, B.R.; Socie, G., IDO in human gut graft-versus-host disease. Biol Blood Marrow Transplant, 2012, 18, (1), 150-155.
22. Ball, H.J.; Sanchez-Perez, A.; Weiser, S.; Austin, C.J.; Astelbauer, F.; Miu, J.; McQuillan, J.A.; Stocker, R.; Jermiin, L.S.; Hunt, N.H., Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene, 2007, 396, (1), 203-213.
23. Metz, R.; Duhadaway, J.B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A.J.; Prendergast, G.C., Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res, 2007, 67, (15), 7082-7087.
24. Pilotte, L.; Larrieu, P.; Stroobant, V.; Colau, D.; Dolusic, E.; Frederick, R.; De Plaen, E.; Uyttenhove, C.; Wouters, J.; Masereel, B.; Van den Eynde, B.J., Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A., 2012, 109, (7), 2497-2502.
25. Opitz, C.A.; Litzenburger, U.M.; Sahm, F.; Ott, M.; Tritschler, I.; Trump, S.; Schumacher, T.; Jestaedt, L.; Schrenk, D.; Weller, M.; Jugold, M.; Guillemin, G.J.; Miller, C.L.; Lutz, C.; Radlwimmer, B.; Lehmann, I.; von Deimling, A.; Wick, W.; Platten, M., An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 2011, 478, (7368), 197-203.
26. Nguyen, N.T.; Kimura, A.; Nakahama, T.; Chinen, I.; Masuda, K.; Nohara, K.; Fujii-Kuriyama, Y.; Kishimoto, T., Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, (46), 19961-19966.
27. Prendergast, G.C.; Chang, M.Y.; Mandik-Nayak, L.; Metz, R.; Muller, A.J., Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem, 2011, 18, (15), 2257-2262.
28. Xu, H.; Oriss, T.B.; Fei, M.; Henry, A.C.; Melgert, B.N.; Chen, L.; Mellor, A.L.; Munn, D.H.; Irvin, C.G.; Ray, P.; Ray, A., Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, (18), 6690-6695.
29. Prendergast, G.C.; Metz, R.; Muller, A.J., Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol, 2010, 176, (5), 2082-2087.
30. Muller, A.J.; Sharma, M.D.; Chandler, P.R.; Duhadaway, J.B.; Everhart, M.E.; Johnson, B.A., 3rd; Kahler, D.J.; Pihkala, J.; Soler, A.P.; Munn, D.H.; Prendergast, G.C.; Mellor, A.L., Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, (44), 17073-17078.
31. Jung, I.D.; Lee, M.G.; Chang, J.H.; Lee, J.S.; Jeong, Y.I.; Lee, C.M.; Park, W.S.; Han, J.; Seo, S.K.; Lee, S.Y.; Park, Y.M., Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. J. Immunol., 2009, 182, (5), 3146-3154.
32. Tattevin, P.; Monnier, D.; Tribut, O.; Dulong, J.; Bescher, N.; Mourcin, F.; Uhel, F.; Le Tulzo, Y.; Tarte, K., Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J Infect Dis, 2010, 201, (6), 956-966.
33. Schefold, J.C.; Zeden, J.P.; Fotopoulou, C.; von Haehling, S.; Pschowski, R.; Hasper, D.; Volk, H.D.; Schuett, C.; Reinke, P., Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, 24, (6), 1901-1908.
34. Lahdou, I.; Sadeghi, M.; Daniel, V.; Schenk, M.; Renner, F.; Weimer, R.; Lob, S.; Schmidt, J.; Mehrabi, A.; Schnitzler, P.; Konigsrainer, A.; Dohler, B.; Opelz, G.; Terness, P., Increased pretransplantation plasma kynurenine levels do not protect from but predict acute kidney allograft rejection. Hum. Immunol., 2010, 71, (11), 1067-1072.
35. Braun, D.; Longman, R.S.; Albert, M.L., A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood, 2005, 106, (7), 2375-2381.
36. Carlin, J.M.; Borden, E.C.; Sondel, P.M.; Byrne, G.I., Biologic-responsemodifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J. Immunol., 1987, 139, (7), 2414-2418.
37. Byrne, G.I.; Lehmann, L.K.; Kirschbaum, J.G.; Borden, E.C.; Lee, C.M.; Brown, R.R., Induction of tryptophan degradation in vitro and in vivo: a γ-interferon-stimulated activity. J Interferon Res, 1986, 6, (4), 389-396.
38. Du, M.X.; Sotero-Esteva, W.D.; Taylor, M.W., Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-γ. J. Interferon Cytokine Res., 2000, 20, (2), 133-142.
39. Tas, S.W.; Vervoordeldonk, M.J.; Hajji, N.; Schuitemaker, J.H.; van der Sluijs, K.F.; May, M.J.; Ghosh, S.; Kapsenberg, M.L.; Tak, P.P.; de Jong, E.C., Noncanonical NF-κB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood, 2007, 110, (5), 1540-1549.
40. Lim, H.; Paria, B.C.; Das, S.K.; Dinchuk, J.E.; Langenbach, R.; Trzaskos, J.M.; Dey, S.K., Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell, 1997, 91, (2), 197-208.
41. Rocca, B.; FitzGerald, G.A., Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol, 2002, 2, (5), 603-630.
42. Cesario, A.; Rocca, B.; Rutella, S., The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr Med Chem, 2011, 18, (15), 2263-2271.
43. Sayama, S.; Yoshida, R.; Oku, T.; Imanishi, J.; Kishida, T.; Hayaishi, O., Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. Proc. Natl. Acad. Sci. U. S. A., 1981, 78, (12), 7327-7330.
44. Marshall, B.; Keskin, D.B.; Mellor, A.L., Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme. BMC Biochem, 2001, 2, (1), 5.
45. Mukherjee, P.; Basu, G.D.; Tinder, T.L.; Subramani, D.B.; Bradley, J.M.; Arefayene, M.; Skaar, T.; De Petris, G., Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J. Immunol., 2009, 182, (1), 216-224.
46. Basu, G.D.; Tinder, T.L.; Bradley, J.M.; Tu, T.; Hattrup, C.L.; Pockaj, B.A.; Mukherjee, P., Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol., 2006, 177, (4), 2391-2402.
47. Alberati-Giani, D.; Malherbe, P.; Ricciardi-Castagnoli, P.; Kohler, C.; Denis-Donini, S.; Cesura, A.M., Differential regulation of indoleamine 2,3-dioxygenase expression by nitric oxide and inflammatory mediators in IFN-γ-activated murine macrophages and microglial cells. J. Immunol., 1997, 159, (1), 419-426.
48. Thomas, S.R.; Mohr, D.; Stocker, R., Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-γ primed mononuclear phagocytes. J. Biol. Chem., 1994, 269, (20), 14457-14464.
49. Orabona, C.; Pallotta, M.T.; Grohmann, U., Different partners, opposite outcomes: A new perspective of IDO's immunobiology. Mol Med, 2012, 18, 834-842.
50. Li, M.O.; Flavell, R.A., TGF-β: a master of all T cell trades. Cell, 2008, 134, (3), 392-404.
51. Pallotta, M.T.; Orabona, C.; Volpi, C.; Vacca, C.; Belladonna, M.L.; Bianchi, R.; Servillo, G.; Brunacci, C.; Calvitti, M.; Bicciato, S.; Mazza, E.M.; Boon, L.; Grassi, F.; Fioretti, M.C.; Fallarino, F.; Puccetti, P.; Grohmann, U., Indoleamine 2,3-dioxygenase is a signaling protein in longterm tolerance by dendritic cells. Nat. Immunol., 2011, 12, (9), 870-878.
52. Yuan, W.; Collado-Hidalgo, A.; Yufit, T.; Taylor, M.; Varga, J., Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-β: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J. Cell. Physiol., 1998, 177, (1), 174-186.
53. Belladonna, M.L.; Volpi, C.; Bianchi, R.; Vacca, C.; Orabona, C.; Pallotta, M.T.; Boon, L.; Gizzi, S.; Fioretti, M.C.; Grohmann, U.; Puccetti, P., Cutting edge: Autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol., 2008, 181, (8), 5194-5198.
54. Belladonna, M.L.; Orabona, C.; Grohmann, U.; Puccetti, P., TGF-β and kynurenines as the key to infectious tolerance. Trends Mol. Med., 2009, 15, (2), 41-49.
55. Orabona, C.; Pallotta, M.T.; Volpi, C.; Fallarino, F.; Vacca, C.; Bianchi, R.; Belladonna, M.L.; Fioretti, M.C.; Grohmann, U.; Puccetti, P., SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, (52), 20828-20833.
56. Orabona, C.; Grohmann, U.; Belladonna, M.L.; Fallarino, F.; Vacca, C.; Bianchi, R.; Bozza, S.; Volpi, C.; Salomon, B.L.; Fioretti, M.C.; Romani, L.; Puccetti, P., CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol., 2004, 5, (11), 1134-1142.
57. Chen, M.; Shabashvili, D.; Nawab, A.; Yang, S.X.; Dyer, L.M.; Brown, K.D.; Hollingshead, M.; Hunter, K.W.; Kaye, F.J.; Hochwald, S.N.; Marquez, V.E.; Steeg, P.; Zajac-Kaye, M., DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. Mol Cancer Ther, 2012, 11, (2), 370-382.
58. Frumento, G.; Rotondo, R.; Tonetti, M.; Damonte, G.; Benatti, U.; Ferrara, G.B., Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med., 2002, 196, (4), 459-468.
59. Molano, A.; Illarionov, P.A.; Besra, G.S.; Putterman, C.; Porcelli, S.A., Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase. Immunol. Lett., 2008, 117, (1), 81-90.
60. Adikari, S.B.; Lian, H.; Link, H.; Huang, Y.M.; Xiao, B.G., Interferon-γ-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin. Exp. Immunol., 2004, 138, (2), 230-236.
61. Manlapat, A.K.; Kahler, D.J.; Chandler, P.R.; Munn, D.H.; Mellor, A.L., Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells. Eur. J. Immunol., 2007, 37, (4), 1064-1071.
62. Romani, L.; Fallarino, F.; De Luca, A.; Montagnoli, C.; D'Angelo, C.; Zelante, T.; Vacca, C.; Bistoni, F.; Fioretti, M.C.; Grohmann, U.; Segal, B.H.; Puccetti, P., Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature, 2008, 451, (7175), 211-215.
63. Fallarino, F.; Grohmann, U.; You, S.; McGrath, B.C.; Cavener, D.R.; Vacca, C.; Orabona, C.; Bianchi, R.; Belladonna, M.L.; Volpi, C.; Santamaria, P.; Fioretti, M.C.; Puccetti, P., The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J. Immunol., 2006, 176, (11), 6752-6761.
64. Puccetti, P.; Grohmann, U., IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation. Nat. Rev. Immunol., 2007, 7, (10), 817-823.
65. Munn, D.H.; Shafizadeh, E.; Attwood, J.T.; Bondarev, I.; Pashine, A.; Mellor, A.L., Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med., 1999, 189, (9), 1363-1372.
66. Munn, D.H.; Sharma, M.D.; Baban, B.; Harding, H.P.; Zhang, Y.; Ron, D.; Mellor, A.L., GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity, 2005, 22, (5), 633-642.
67. Terness, P.; Bauer, T.M.; Rose, L.; Dufter, C.; Watzlik, A.; Simon, H.; Opelz, G., Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med., 2002, 196, (4), 447-457.
68. Iken, K.; Liu, K.; Liu, H.; Bizargity, P.; Wang, L.; Hancock, W.W.; Visner, G.A., IDO and metabolites protect mouse lung allografts and impair calcium mobilization of T cells. Am J Respir Cell Mol Biol, 2012, Apr 19. [Epub ahead of print].
69. Wang, Y.; Liu, H.; McKenzie, G.; Witting, P.K.; Stasch, J.P.; Hahn, M.; Changsirivathanathamrong, D.; Wu, B.J.; Ball, H.J.; Thomas, S.R.; Kapoor, V.; Celermajer, D.S.; Mellor, A.L.; Keaney, J.F., Jr.; Hunt, N.H.; Stocker, R., Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat. Med., 2010, 16, (3), 279-285.
70. Barth, M.C.; Ahluwalia, N.; Anderson, T.J.; Hardy, G.J.; Sinha, S.; Alvarez-Cardona, J.A.; Pruitt, I.E.; Rhee, E.P.; Colvin, R.A.; Gerszten, R.E., Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J. Biol. Chem., 2009, 284, (29), 19189-19195.
71. Changsirivathanathamrong, D.; Wang, Y.; Rajbhandari, D.; Maghzal, G.J.; Mak, W.M.; Woolfe, C.; Duflou, J.; Gebski, V.; dos Remedios, C.G.; Celermajer, D.S.; Stocker, R., Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. Crit Care Med, 2011, 39, (12), 2678-2683.
72. Levina, V.; Su, Y.; Gorelik, E., Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation. Clin Dev Immunol, 2012, 2012, 173029.
73. Muller, A.J.; Malachowski, W.P.; Prendergast, G.C., Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with smallmolecule inhibitors. Expert Opin Ther Targets, 2005, 9, (4), 831-849.
74. Di Pucchio, T.; Danese, S.; De Cristofaro, R.; Rutella, S., Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. Expert Opin. Ther. Pat., 2010, 20, (2), 229-250.
75. Baban, B.; Chandler, P.; McCool, D.; Marshall, B.; Munn, D.H.; Mellor, A.L., Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol., 2004, 61, (2), 67-77.
76. Muller, A.J.; Scherle, P.A., Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer, 2006, 6, (8), 613-625.
77. Sugimoto, H.; Oda, S.; Otsuki, T.; Hino, T.; Yoshida, T.; Shiro, Y., Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, (8), 2611-2616.
78. Jia, L.; Schweikart, K.; Tomaszewski, J.; Page, J.G.; Noker, P.E.; Buhrow, S.A.; Reid, J.M.; Ames, M.M.; Munn, D.H., Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption. Food Chem. Toxicol., 2008, 46, (1), 203-211.
79. Hou, D.Y.; Muller, A.J.; Sharma, M.D.; DuHadaway, J.; Banerjee, T.; Johnson, M.; Mellor, A.L.; Prendergast, G.C.; Munn, D.H., Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyltryptophan correlates with antitumor responses. Cancer Res, 2007, 67, (2), 792-801.
80. Witkiewicz, A.; Williams, T.; Cozzitorto, J.; Durkan, B.; Showalter, S.; CJ, Y.; JR, B., Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J. Am. Coll. Surg., 2008, 206, (5), 849-854.
81. Lob, S.; Konigsrainer, A.; Zieker, D.; Brucher, B.L.; Rammensee, H.G.; Opelz, G.; Terness, P., IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother, 2009, 58, 153-157.
82. Lob, S.; Konigsrainer, A.; Schafer, R.; Rammensee, H.G.; Opelz, G.; Terness, P., Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood, 2008, 111, (4), 2152-2154.
83. Qian, F.; Villella, J.; Wallace, P.K.; Mhawech-Fauceglia, P.; Tario, J.D., Jr.; Andrews, C.; Matsuzaki, J.; Valmori, D.; Ayyoub, M.; Frederick, P.J.; Beck, A.; Liao, J.; Cheney, R.; Moysich, K.; Lele, S.; Shrikant, P.; Old, L.J.; Odunsi, K., Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of Tcell proliferation in human epithelial ovarian cancer. Cancer Res, 2009, 69, (13), 5498-5504.
84. Allen, J.A.; Peterson, A.; Sufit, R.; Hinchcliff, M.E.; Mahoney, J.M.; Wood, T.A.; Miller, F.W.; Whitfield, M.L.; Varga, J., Post-epidemic eosinophiliamyalgia syndrome associated with L-tryptophan. Arthritis Rheum, 2011, 63, (11), 3633-3639.
85. Travers, M.T.; Gow, I.F.; Barber, M.C.; Thomson, J.; Shennan, D.B., Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells. Biochim Biophys Acta, 2004, 1661, (1), 106-112.
86. Kudo, Y.; Boyd, C.A., The role of L-tryptophan transport in L-tryptophan degradation by indoleamine 2,3-dioxygenase in human placental explants. J. Physiol., 2001, 531, (Pt 2), 417-423.
87. Agaugue, S.; Perrin-Cocon, L.; Coutant, F.; Andre, P.; Lotteau, V., 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J. Immunol., 2006, 177, (4), 2061-2071.
88. Vaccari, M.; Boasso, A.; Fenizia, C.; Fuchs, D.; Hryniewicz, A.; Morgan, T.; Weiss, D.; Doster, M.N.; Heraud, J.M.; Shearer, G.M.; Franchini, G., Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2',3'-dideoxyinosine and stavudine following cytotoxic-T- lymphocyte-associated antigen 4 and indoleamine 2,3-dioxygenase blockade. J Virol, 2012, 86, (1), 108-113.
89. Chang, M.Y.; Smith, C.; Duhadaway, J.B.; Pyle, J.R.; Boulden, J.; Peralta Soler, A.; Muller, A.J.; Laury-Kleintop, L.D.; Prendergast, G.C., Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther, 2011, 12, (12).
90. Liu, X.; Shin, N.; Koblish, H.K.; Yang, G.; Wang, Q.; Wang, K.; Leffet, L.; Hansbury, M.J.; Thomas, B.; Rupar, M.; Waeltz, P.; Bowman, K.J.; Polam, P.; Sparks, R.B.; Yue, E.W.; Li, Y.; Wynn, R.; Fridman, J.S.; Burn, T.C.; Combs, A.P.; Newton, R.C.; Scherle, P.A., Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood, 2010, 115, (17), 3520-3530.
91. Newton, R.C.; Scherle, P.A.; Bowman, K.; Liu, X.; Beatty, G.L.; O'Dwyer, P.J.; Gajewski, T.; Bowman, J.; Schaub, R.; Leopold, L., Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. ASCO Meeting Abstracts, 2012, 30, (15-suppl), 2500.
92. Huang, T.T.; Yen, M.C.; Lin, C.C.; Weng, T.Y.; Chen, Y.L.; Lin, C.M.; Lai, M.D., Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. Cancer Sci, 2011, 102, (12), 2214-2220.
93. Silver, R.M.; McKinley, K.; Smith, E.A.; Quearry, B.; Harati, Y.; Sternberg, E.M.; Heyes, M.P., Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome. Arthritis Rheum, 1992, 35, (9), 1097-1105.
94. Lutzky, V.; Hannawi, S.; Thomas, R., Cells of the synovium in rheumatoid arthritis. Dendritic cells. Arthritis Res. Ther., 2007, 9, (4), 219.
95. Rutella, S.; De Cristofaro, R.; Ferraccioli, G., Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Hum. Immunol., 2009, 70, (5), 360-373.
96. Kroger, H.; Dietrich, A.; Gratz, R.; Wild, A.; Ehrlich, W., The effect of tryptophan plus methionine, 5-azacytidine, and methotrexate on adjuvant arthritis of rat. Gen Pharmacol, 1999, 33, (2), 195-201.
97. Szanto, S.; Koreny, T.; Mikecz, K.; Glant, T.T.; Szekanecz, Z.; Varga, J., Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res. Ther., 2007, 9, (3), R50.
98. Criado, G.; Simelyte, E.; Inglis, J.J.; Essex, D.; Williams, R.O., Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis. Arthritis Rheum, 2009, 60, (5), 1342-1351.
99. Park, M.J.; Min, S.Y.; Park, K.S.; Cho, Y.G.; Cho, M.L.; Jung, Y.O.; Park, H.S.; Chang, S.H.; Cho, S.G.; Min, J.K.; Park, S.H.; Kim, H.Y., Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model. Arthritis Res. Ther., 2008, 10, (1), R11.
100. Scott, G.N.; DuHadaway, J.; Pigott, E.; Ridge, N.; Prendergast, G.C.; Muller, A.J.; Mandik-Nayak, L., The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J. Immunol., 2009, 182, (12), 7509-7517.
101. Korganow, A.S.; Ji, H.; Mangialaio, S.; Duchatelle, V.; Pelanda, R.; Martin, T.; Degott, C.; Kikutani, H.; Rajewsky, K.; Pasquali, J.L.; Benoist, C.; Mathis, D., From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity, 1999, 10, (4), 451-461.
102. Pigott, E.; Mandik-Nayak, L., Addition of an indoleamine-2,3,-dioxygenase inhibitor to B cell depletion therapy blocks autoreactive B cell activation and recurrence of arthritis. Arthritis Rheum, 2012, doi: 10.1002/art.34406.
103. Bianco, N.R.; Kim, S.H.; Ruffner, M.A.; Robbins, P.D., Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum, 2009, 60, (2), 380-389.
104. Chen, S.Y.; Wu, C.L.; Lai, M.D.; Lin, C.C.; Yo, Y.T.; Jou, I.M.; Lee, C.H.; Weng, C.T.; Shiau, A.L.; Wang, C.R., Amelioration of rat collagen-induced arthritis through CD4+ T cells apoptosis and synovial interleukin-17 reduction by indoleamine 2,3-dioxygenase gene therapy. Hum Gene Ther, 2011, 22, (2), 145-154.
105. De Almeida, D.E.; Ling, S.; Pi, X.; Hartmann-Scruggs, A.M.; Pumpens, P.; Holoshitz, J., Immune dysregulation by the rheumatoid arthritis shared epitope. J. Immunol., 2010, 185, (3), 1927-1934.
106. Holoshitz, J.; De Almeida, D.E.; Ling, S., A role for calreticulin in the pathogenesis of rheumatoid arthritis. Ann N Y Acad Sci, 2010, 1209, 91-98.
107. Lin, H.S.; Hu, C.Y.; Chan, H.Y.; Liew, Y.Y.; Huang, H.P.; Lepescheux, L.; Bastianelli, E.; Baron, R.; Rawadi, G.; Clement-Lacroix, P., Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collageninduced arthritis in rodents. Br J Pharmacol, 2007, 150, (7), 862-872.
108. Misaki, K.; Morinobu, A.; Saegusa, J.; Kasagi, S.; Fujita, M.; Miyamoto, Y.; Matsuki, F.; Kumagai, S., Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice. Arthritis Res. Ther., 2011, 13, (3), R77.
109. Reddy, P.; Sun, Y.; Toubai, T.; Duran-Struuck, R.; Clouthier, S.G.; Weisiger, E.; Maeda, Y.; Tawara, I.; Krijanovski, O.; Gatza, E.; Liu, C.; Malter, C.; Mascagni, P.; Dinarello, C.A.; Ferrara, J.L., Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest., 2008, 118, (7), 2562-2573.
110. Paniagua, R.T.; Sharpe, O.; Ho, P.P.; Chan, S.M.; Chang, A.; Higgins, J.P.; Tomooka, B.H.; Thomas, F.M.; Song, J.J.; Goodman, S.B.; Lee, D.M.; Genovese, M.C.; Utz, P.J.; Steinman, L.; Robinson, W.H., Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest., 2006, 116, (10), 2633-2642.
111. Koyama, K.; Hatsushika, K.; Ando, T.; Sakuma, M.; Wako, M.; Kato, R.; Haro, H.; Sugiyama, H.; Hamada, Y.; Ogawa, H.; Nakao, A., Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol, 2007, 17, (4), 306-310.
112. Vernon, M.R.; Pearson, L.; Atallah, E., Resolution of rheumatoid arthritis symptoms with imatinib mesylate. J Clin Rheumatol, 2009, 15, (5), 267.
113. Pereira, I.; Fialho, S.; Castro, G.; Zimmermann, A., Imatinib mesylate induces clinical remission in rheumatoid arthritis. Joint Bone Spine, 2010, 77, (4), 372-373.
114. Nazarinia, M.A.; Ghaffarpasand, F.; Seraj, S.R.; Heiran, H.R.; Khojasteh, H.N., Imatinib treatment of ankylosing spondylitis in a patient resistant to NSAIDs and infliximab. J Clin Rheumatol, 2010, 16, (3), 140-142.
115. Balachandran, V.P.; Cavnar, M.J.; Zeng, S.; Bamboat, Z.M.; Ocuin, L.M.; Obaid, H.; Sorenson, E.C.; Popow, R.; Ariyan, C.; Rossi, F.; Besmer, P.; Guo, T.; Antonescu, C.R.; Taguchi, T.; Yuan, J.; Wolchok, J.D.; Allison, J.P.; DeMatteo, R.P., Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med., 2011, 17, (9), 1094-1100.
116. Seo, S.K.; Choi, J.H.; Kim, Y.H.; Kang, W.J.; Park, H.Y.; Suh, J.H.; Choi, B.K.; Vinay, D.S.; Kwon, B.S., 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med., 2004, 10, (10), 1088-1094.
117. Kavousanaki, M.; Makrigiannakis, A.; Boumpas, D.; Verginis, P., Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy. Arthritis Rheum, 2010, 62, (1), 53-63.
118. Zhu, L.; Ji, F.; Wang, Y.; Zhang, Y.; Liu, Q.; Zhang, J.Z.; Matsushima, K.; Cao, Q.; Zhang, Y., Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J. Immunol., 2006, 177, (11), 8226-8233.
119. Schroecksnadel, K.; Kaser, S.; Ledochowski, M.; Neurauter, G.; Mur, E.; Herold, M.; Fuchs, D., Increased degradation of tryptophan in blood of patients with rheumatoid arthritis. J Rheumatol, 2003, 30, (9), 1935-1939.
120. Bertazzo, A.; Punzi, L.; Bertazzolo, N.; Pianon, M.; Pozzuoli, A.; Costa, C.V.; Allegri, G., Tryptophan catabolism in synovial fluid of various arthropathies and its relationship with inflammatory cytokines. Adv Exp Med Biol, 1999, 467, 565-570.
121. Forrest, C.M.; Kennedy, A.; Stone, T.W.; Stoy, N.; Darlington, L.G., Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. Adv Exp Med Biol, 2003, 527, 287-295.
122. Ozkan, Y.; Mete, G.; Sepici-Dincel, A.; Sepici, V.; Simsek, B., Tryptophan degradation and neopterin levels in treated rheumatoid arthritis patients. Clin Rheumatol, 2012, 31, (1), 29-34.
123. Schroecksnadel, K.; Winkler, C.; Duftner, C.; Wirleitner, B.; Schirmer, M.; Fuchs, D., Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol, 2006, 25, (3), 334-337.
124. Kurz, K.; Herold, M.; Winkler, C.; Klotz, W.; Russe, E.; Fuchs, D., Effects of adalimumab therapy on disease activity and interferon-gamma-mediated biochemical pathways in patients with rheumatoid arthritis. Autoimmunity, 2011, 44, (3), 235-242.
125. Park, M.K.; Oh, H.J.; Heo, Y.M.; Park, E.M.; Cho, M.L.; Kim, H.Y.; Park, S.H., Myeloid differentiation primary response protein 88 blockade upregulates indoleamine 2,3-dioxygenase expression in rheumatoid synovial fibroblasts. Exp Mol Med, 2011, 43, (8), 446-454.
126. Ohtsuka, K.; Gray, J.D.; Stimmler, M.M.; Toro, B.; Horwitz, D.A., Decreased production of TGF-β by lymphocytes from patients with systemic lupus erythematosus. J. Immunol., 1998, 160, (5), 2539-2545.
127. Yang, B.C.; Wang, Y.S.; Lin, L.C.; Liu, M.F., Induction of apoptosis and cytokine gene expression in T-cell lines by sera of patients with systemic lupus erythematosus. Scand J Immunol, 1997, 45, (1), 96-102.
128. Pertovaara, M.; Hasan, T.; Raitala, A.; Oja, S.S.; Yli-Kerttula, U.; Korpela, M.; Hurme, M., Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin. Exp. Immunol., 2007, 150, (2), 274-278.
129. Widner, B.; Sepp, N.; Kowald, E.; Ortner, U.; Wirleitner, B.; Fritsch, P.; Baier-Bitterlich, G.; Fuchs, D., Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology, 2000, 201, (5), 621-630.
130. Del Papa, N.; Quirici, N.; Scavullo, C.; Gianelli, U.; Corti, L.; Vitali, C.; Ferri, C.; Giuggioli, D.; Manfredi, A.; Maglione, W.; Onida, F.; Colaci, M.; Bosari, S.; Lambertenghi Deliliers, G., Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis. J Rheumatol, 2010, 37, (10), 2053-2063.
131. Rutella, S.; De Santis, M.; Bonanno, G.; Procoli, A.; Mariotti, A.; Corallo, M.; Novarese, L.; Bosello, S.; Scambia, G.; De Cristofaro, R.; Ferraccioli, G., Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with inflammation in systemic sclerosis. J. Immunol., 2011, 186, (Meeting Abstracts 1), 115.115.
132. Seror, R.; Ravaud, P.; Bowman, S.J.; Baron, G.; Tzioufas, A.; Theander, E.; Gottenberg, J.E.; Bootsma, H.; Mariette, X.; Vitali, C., EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis, 2010, 69, (6), 1103-1109.
133. Bombardieri, M.; Barone, F.; Humby, F.; Kelly, S.; McGurk, M.; Morgan, P.; Challacombe, S.; De Vita, S.; Valesini, G.; Spencer, J.; Pitzalis, C., Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren's syndrome. J. Immunol., 2007, 179, (7), 4929-4938.
134. Ozaki, Y.; Amakawa, R.; Ito, T.; Iwai, H.; Tajima, K.; Uehira, K.; Kagawa, H.; Uemura, Y.; Yamashita, T.; Fukuhara, S., Alteration of peripheral blood dendritic cells in patients with primary Sjogren's syndrome. Arthritis Rheum, 2001, 44, (2), 419-431.
135. Gottenberg, J.E.; Cagnard, N.; Lucchesi, C.; Letourneur, F.; Mistou, S.; Lazure, T.; Jacques, S.; Ba, N.; Ittah, M.; Lepajolec, C.; Labetoulle, M.; Ardizzone, M.; Sibilia, J.; Fournier, C.; Chiocchia, G.; Mariette, X., Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, (8), 2770-2775.
136. Wildenberg, M.E.; Welzen-Coppens, J.M.; van Helden-Meeuwsen, C.G.; Bootsma, H.; Vissink, A.; van Rooijen, N.; van de Merwe, J.P.; Drexhage, H.A.; Versnel, M.A., Increased frequency of CD16+ monocytes and the presence of activated dendritic cells in salivary glands in primary Sjogren's Syndrome. Ann Rheum Dis, 2009, 68, (3), 420-426.
137. Manoussakis, M.N.; Boiu, S.; Korkolopoulou, P.; Kapsogeorgou, E.K.; Kavantzas, N.; Ziakas, P.; Patsouris, E.; Moutsopoulos, H.M., Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum, 2007, 56, (12), 3977-3988.
138. Wildenberg, M.E.; van Helden-Meeuwsen, C.G.; van de Merwe, J.P.; Drexhage, H.A.; Versnel, M.A., Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur. J. Immunol., 2008, 38, (7), 2024-2033.
139. Pertovaara, M.; Raitala, A.; Uusitalo, H.; Pukander, J.; Helin, H.; Oja, S.S.; Hurme, M., Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjogren's syndrome. Clin. Exp. Immunol., 2005, 142, (1), 155-161.
140. Vitali, C.; Bombardieri, S.; Jonsson, R.; Moutsopoulos, H.M.; Alexander, E.L.; Carsons, S.E.; Daniels, T.E.; Fox, P.C.; Fox, R.I.; Kassan, S.S.; Pillemer, S.R.; Talal, N.; Weisman, M.H., Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis, 2002, 61, (6), 554-558.
141. Schwarcz, R.; Bruno, J.P.; Muchowski, P.J.; Wu, H.Q., Kynurenines in the mammalian brain: when physiology meets pathology. Nature reviews. Neuroscience, 2012.
142. Muller, A.J.; Mandik-Nayak, L.; Prendergast, G.C., Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy, 2010, 2, (3), 293-297.
143. Terness, P.; Chuang, J.J.; Opelz, G., The immunoregulatory role of IDOproducing human dendritic cells revisited. Trends Immunol, 2006, 27, (2), 68-73.
144. Soliman, H.H.; Antonia, S.J.; Sullivan, D.; Vanahanian, N.; Link, C., Overcoming tumor antigen anergy in human malignancies using the novel indoleamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-Dtryptophan (1MT). J. Clin. Oncol., 2009, 27, (15S), 3004A.
145. Thomaidis, T.; Schorn, C.; Flaig, W.; Lingg, G.; Schonhals, E.; Klingel, R.; Galle, P.R.; Schwarting, A., Immunoadsorption with tryptophan columns: a therapeutic option for the treatment of rheumatoid arthritis with septic complications. J Clin Apher, 2009, 24, (1), 37-41.
146. Xu, H.; Zhang, G.X.; Ciric, B.; Rostami, A., IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol. Lett., 2008, 121, (1), 1-6.
147. Fallarino, F.; Grohmann, U.; Puccetti, P., Indoleamine 2,3-dioxygenase: From catalyst to signaling function. Eur. J. Immunol., 2012, 42, (8), 1932-1937.